Media about us
-
Struggling Marinus gets a bump out of a positive PhII snapshot
24 January 2017
A little more than six months since its stock price was crushed by a failed late-stage program for its leading — and only — drug, tiny biotech microcap Marinus $MRNS saw its shares shoot up this morning after it offered a positive Phase II snapshot on a handful of patients who suffer from a rare genetic ailment.
-
Marinus gets a lifeline with new ganaxolone data
24 January 2017
Micro cap Marinus Pharmaceuticals was up 28% premarket this morning on positive, early data from its midstage test of ganaxolone in a rare condition that causes severe seizures.
-
JP Morgan Healthcare Conference, Day One: Genomic Health, Meridian Bioscience, Qiagen
11 January 2017
The 35th Annual JP Morgan Healthcare Conference began here Monday with several life science research tools and diagnostic firms making presentations to investors and other attendees.
-
Epic uncovers prostate cancer biomarker
09 January 2017
Biotech company Epic Sciences’ focus on circulating tumor cells (CTCs) will not only advance the clinical use of liquid biopsies and improve how metastatic cancer is treated, it says, but also identified a unique CTC biomarker in patients with metastatic prostate cancer who respond to PARP inhibitors cancer drugs in development.
-
Raindrop Vision Procedure Designed to Reduce or Eliminate Reading Glasses Now Available in Alabama.
05 January 2017
The All-New Raindrop® Near Vision Inlay is designed to improve near vision so you can once again see fine print, menus and your phone without the hassle of reading glasses.
-
Pfizer Inc. Considerable Stocks on Returns- Horizon Pharma plc
29 December 2016
Pfizer Inc. (NYSE:PFE) , stock eased up around 0.15% in early session as its gaining volume of 11.21 Million. US pharma giant, Pfizer (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.
-
Pfizer Inc. and NovaMedica have completed the last stage of negotiations
29 December 2016
Pfizer Inc. (NYSE:PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.
-
Pfizer and NovaMedica complete strategic partnership
28 December 2016
US pharma giant Pfizer (NYSE: PFE) and Russia’s NovaMedica, a company established in 2012 by Russian high-technology investment fund Rusnano and American healthcare fund Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio.
-
US-Russia Relations: Why Donald Trump is Right to Look East
19 December 2016
US President-elect Donald J Trump has been widely criticised by his liberal critics in the media and by Democratic Party opponents for wanting to normalise his country’s relations with Russia and to adopt a more balanced approach towards Moscow.
-
Nurse to get newly improved cornea inlay to improve near vision
07 December 2016
Diane McTaggart will be among the first Middle Tennesseans to undergo a newly approved device to treat loss of near vision associated with aging, also known as presbyopia. The U.S. Food and Drug Administration approved ReVision Optics' Raindrop Near Vision Inlay — a device that gets implanted in the cornea — this summer. The tiny inlay looks like a small contact lens, albeit smaller than a needle's eye, that is made out of hydrogel material. It's approved for people aged 41 to 65 who need reading glasses for small print but do not glasses for distance vision, and have not had cataract surgery.
